Integra LifeSciences
English:US
Integra LifeSciences
Investor Home
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Contact Us


 
Committee Composition
Chairman of the Board = Chairman of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Under NASDAQ Listing Standards Presiding Director = Presiding Director
  Audit Nominating and Corporate Governance Compensation Finance
Stuart M. Essig, Ph.D. Independent Director Chairman of the Board        
Peter J. Arduini        
Keith Bradley, Ph.D. Independent Director   Member of Nominating and Corporate Governance Committee Committee Chair for Compensation Committee  
Richard E. Caruso, Ph.D. Independent Director        
Barbara B. Hill Independent Director   Member of Nominating and Corporate Governance Committee Member of Compensation Committee  
Lloyd W. Howell, Jr. Independent Director Member of Audit Committee     Member of Finance Committee
Donald E. Morel, Jr., Ph.D. Independent Director     Member of Compensation Committee  
Raymond G. Murphy Independent Director Committee Chair for Audit Committee     Member of Finance Committee
Christian S. Schade Independent Director Member of Audit Committee     Committee Chair for Finance Committee
Christian S. Schade
President and Chief Executive Officer of Aprea AB

CHRISTIAN S. SCHADE has been a director of the Company since 2006. He currently serves as the President and Chief Executive Officer of Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, positions he has held since June 2016. Prior to that, Mr. Schade was the Chief Executive Officer of Novira Therapeutics, Inc., an antiviral drug discovery company focused on first-in-class therapeutics for chronic HBV infection from March 2014 to December 2015 until it was acquired by Johnson & Johnson. Before joining Novira Therapeutics, Inc. in March 2014, he served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc. from September 2011 to July 2013. Omthera was an emerging specialty pharmaceuticals company focused on the clinical development of therapies for dyslipidemia until it was purchased by AstraZeneca Plc in July 2013. From April 2010 to September 2011, Mr. Schade served as Executive Vice President and Chief Financial Officer at NRG Energy, a NYSE listed, S&P 500 wholesale power generation company based in Princeton, NJ. While there, he was responsible for corporate financial functions, including Treasury, Accounting, Tax, Risk, Credit Management and Insurance. Prior to joining NRG, he was Senior Vice President Administration and Chief Financial Officer at Medarex Inc., a NASDAQ listed,Princeton-based biopharmaceutical company. He also helped Medarex to grow to become a leading pharmaceutical development company, raising capital through a series of public capital market and asset monetization transactions. While there, he also oversaw the manufacturing of multiple development/clinical programs and was responsible for the business development team. Before joining Medarex in 2000, Mr. Schade served as Managing Director at Merrill Lynch in London, where he was head of the European Corporate Funding Group and was responsible for certain capital markets activities of Merrill Lynch's European corporate clients. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Indivior, a UK listed spinoff of the pharmaceutical division of the consumer products conglomerate, Reckitt Benckiser. Mr. Schade received an A.B. degree from Princeton University, and received an M.B.A. from the Wharton School at the University of Pennsylvania.

James M. Sullivan Independent Director Presiding Director Member of Audit Committee Committee Chair for Nominating and Corporate Governance Committee